Open AccessAntacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
Author(s) -
Michael Kreuter,
Paolo Spagnolo,
Wim Wuyts,
Elisabetta A. Renzoni,
Dirk Koschel,
Francesco Bonella,
Toby M. Maher,
Martin Kolb,
Derek Weycker,
Klaus-Uwe Kirchgässler,
Ulrich Costabel
Publication year - 2017
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000468546
Subject(s) - medicine , pirfenidone , idiopathic pulmonary fibrosis , gastroenterology , vital capacity , pulmonary function testing , adverse effect , lung , lung function , diffusing capacity
Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate.